|
|
Vol. 12.48 – 7 December, 2023
|
|
|
|
|
|
|
|
Scientists studied the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC) enzyme APOBEC3B on epidermal growth factor receptor-driven lung cancer. [Nature Genetics]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
Following intratracheal aerosol delivery of Cy5-labeled peptide in rhesus macaques, the authors confirmed delivery throughout the respiratory tract.
[Nature Communications]
|
|
|
|
|
|
K329R knockin mice with defective RBM47-ISGylation displayed heightened susceptibility to LPS-induced acute lung injury and lung tumorigenesis.
[Cell Death Discovery]
|
|
|
|
|
|
Human alveolar epithelial cells and macrophages were exposed in vitro to dust and assessed for cytotoxicity and inflammation.
[Respirology]
|
|
|
|
|
|
The angiotensin (Ang)-(1–7)-/Mas axis inhibited TGF-β1-induced lung fibroblast differentiation, inflammation, and fibrosis in bleomycin-treated lung tissue.
[European Journal Of Pharmacology]
|
|
|
|
|
|
|
|
The authors investigated the biological effects of chemically characterized indoor dust extracts using three-dimensional lung cancer cell cultures combining phenotypic and lipidomic analyses.
[Environmental Science & Technology]
|
|
|
|
|
|
Elevated USP13 promoted KRAS-mutant NSCLC metastasis, which was associated with poor prognosis in NSCLC patients.
[Cell Reports]
|
|
|
|
|
|
The binding targets and underlying mechanisms of the differentially expressed miRNAs were verified by in vitro and in vivo experiments.
[Cell Death & Disease]
|
|
|
|
|
|
The in vitro cytotoxicity of the 17 semisynthesized derivatives of renieramycin S against human NSCLC cells in parallel with normal cell lines was evaluated.
[Scientific Reports]
|
|
|
|
|
|
|
|
|
The roles and importance of extracellular vesicles substantially differs between studies, depending on experimental conditions and parent cell origins of extracellular vesicles that modify the nature of their cargo. [Journal Of Nanobiotechnology]
|
|
|
|
|
|
|
|
The therapy is a bispecific antibody targeting EGFR and c-MET, which are believed to be dysregulated in many tumors such as NSCLC. [Fierce Biotech]
|
|
|
|
|
|
|
|
January 22 – 25, 2024 Santa Fe, New Mexico, United States
|
|
|
|
|
|
|
|
|
|
|
Cedars-Sinai – Los Angeles, California, United States
|
|
|
|
|
|
|
University of California, San Francisco – San Francisco, California, United States
|
|
|
|
|
|
|
Indiana University – Indiana, Pennsylvania, United States
|
|
|
|
|
|
|
Rutgers Health – Newark, New Jersey, United States
|
|
|
|
|
|
|
Royal College of Surgeons in Ireland – Dulin, Ireland
|
|
|
|
|
|